Skip to main content

Table 1 Descriptive statistics among all adult hospitalizations and bivariable analysis by aortic stenosis treatment modality among cancer patientsa

From: TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients

Variables Sample Treatment P-value
N = 30,195,722 MM (n = 4,640,563 [99.60%]) TAVR (n = 9318 [0.20%]) SAVR (n = 8852 [0.19%]) TAVR versus MM TAVR vs SAVR
Demographics, no. (%)
 Age, mean (SD) 68.70 (14.30) 68.67 (14.31) 81.00 (7.93) 71.52 (9.35) < 0.001 < 0.001
 Female 15,254,879 (50.52) (50.54) (40.2) (32.61) < 0.001 < 0.001
 Race, nonwhite 7,132,230 (23.62) (23.65) (10.00) (10.97) < 0.001 0.349
 Insurance, non-private 23,380,548 (77.43) (77.4) (93.23) (79.23) < 0.001 < 0.001
Medical history
 Diabetes 6247,495 (20.69) (20.68) (26.02) (20.20) < 0.001 < 0.001
 Hypertension 19,790,276 (65.54) (65.49) (88.13) (81.14) < 0.001 < 0.001
 Hyperlipidemia 11,869,938 (39.31) (39.25) (69.29) (70.20) < 0.001 0.546
 Congestive heart failure 1,926,487 (6.38) (6.33) (34.3) (12.95) < 0.001 < 0.001
 Smoking 332,153 (1.10) (1.10) (0.37) (1.17) < 0.001 0.005
 Depression 3,895,248 (12.90) (12.91) (7.6) (9.43) < 0.001 0.046
 Cirrhosis 742,815 (2.46) (2.47) (1.53) (0.56) 0.009 0.004
 CKD 3–5 4,055,285 (13.43) (13.4) (24.54) (11.55) < 0.001 < 0.001
Outcomes, median (range)
 Mortality, no. (%) 1,201,790 (3.98) (3.99) (1.43) (3.24) < 0.001 < 0.001
 Length of stay, days 5.46 (6.34) 5.45 (6.34) 4.59 (4.56) 9.10 (7.09) < 0.001 < 0.001
 Cost, dollars 60,612.22 (87,774.68) 60,002.30 (86,913.86) 210,106.90 (110,707.70) 219,202.30 (179,519.90) < 0.001 0.065
  1. aMM medical management, TAVR transcatheter aortic valve replacement, SAVR surgical aortic valve replacement, bold = statistically significant, CKD chronic kidney disease